tiprankstipranks
Trending News
More News >

Vaxart Begins Phase 2b Trial for Oral COVID-19 Vaccine

Story Highlights
  • Vaxart began dosing in a 10,000-participant Phase 2b trial for its oral COVID-19 vaccine.
  • The trial is supported by BARDA funding, aiming to evaluate the vaccine’s efficacy and safety.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Vaxart Begins Phase 2b Trial for Oral COVID-19 Vaccine

Confident Investing Starts Here:

Vaxart ( (VXRT) ) has shared an announcement.

On May 27, 2025, Vaxart announced the dosing of the first patient in a significant 10,000-participant Phase 2b clinical trial for its oral COVID-19 vaccine candidate. This trial aims to evaluate the vaccine’s efficacy, safety, and immunogenicity compared to an approved mRNA COVID-19 vaccine. The trial’s progression follows a positive safety review from an independent board, and it is supported by substantial funding from BARDA and NIAID under Project NextGen, highlighting the potential impact on Vaxart’s market positioning and contribution to next-generation COVID-19 vaccine development.

The most recent analyst rating on (VXRT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.

Spark’s Take on VXRT Stock

According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.

Vaxart’s stock score is primarily driven by strong revenue growth and strategic initiatives such as clinical trial advancements and the proposed reverse stock split. However, significant challenges in profitability, cash flow management, and technical indicators suggest bearish momentum. The risk of NASDAQ delisting also weighs heavily on the stock. While strategic initiatives and cash management efforts offer some hope for future stability, current risks remain substantial.

To see Spark’s full report on VXRT stock, click here.

More about Vaxart

Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using its proprietary delivery platform. The company’s vaccines are designed to be administered as pills, which do not require refrigeration and eliminate needle-stick injury risks. Vaxart’s development programs include vaccines for coronavirus, norovirus, influenza, and a therapeutic vaccine for HPV, marking its first immune-oncology indication.

Average Trading Volume: 1,848,151

Technical Sentiment Signal: Sell

Current Market Cap: $105.2M

Find detailed analytics on VXRT stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1